INVA
Innoviva, Inc. NASDAQ Listed Oct 5, 2004$21.14
+0.43%
vs $21.05
Mkt Cap $1.6B
52w Low $16.52
53.5% of range
52w High $25.15
50d MA $21.19
200d MA $21.76
P/E (TTM)
5.2x
EV/EBITDA
1.8x
P/B
1.2x
Debt/Equity
0.2x
ROE
23.1%
P/FCF
9.2x
RSI (14)
53.40
ATR (14)
$0.42
Beta
0.40
50d MA
$21.19
200d MA
$21.76
Avg Volume
729.8K
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
1350 Old Bayshore Highway · Burlingame, CA 94010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AMC | 0.44 | -1.14 | -361.5% | 20.51 | +3.0% | +2.9% | -2.8% | +0.8% | +0.3% | +0.3% | — |
| May 6, 2026 | AMC | 0.43 | 0.44 | +2.3% | 22.52 | +4.3% | +1.2% | +0.4% | -1.6% | +1.0% | +1.8% | — |
| Feb 25, 2026 | AMC | 0.34 | 1.94 | +470.6% | 24.24 | +3.1% | -2.9% | -2.5% | -0.6% | -2.3% | +1.9% | — |
| Nov 5, 2025 | AMC | 0.46 | 1.08 | +134.8% | 18.23 | +8.9% | +12.9% | +1.4% | +0.0% | +4.9% | +1.7% | — |
| Aug 6, 2025 | AMC | 0.57 | 0.77 | +35.1% | 18.25 | +0.1% | +1.2% | -0.7% | +7.1% | +2.2% | +2.6% | — |
| May 7, 2025 | AMC | 0.29 | 0.25 | -13.8% | 18.74 | +0.1% | -0.9% | -0.1% | +0.3% | -1.9% | -1.4% | — |
| Feb 26, 2025 | AMC | 0.34 | 0.57 | +67.6% | 17.90 | +0.8% | -2.0% | +2.1% | -0.7% | -1.2% | +0.2% | — |
| Nov 6, 2024 | AMC | 0.27 | 0.02 | -92.6% | 19.92 | -0.2% | +0.4% | +0.9% | -0.3% | +1.0% | -1.1% | — |
| Jul 31, 2024 | AMC | 0.24 | 0.68 | +183.3% | 18.84 | -4.4% | +2.4% | -1.1% | -4.0% | +0.3% | -1.3% | — |
| May 8, 2024 | AMC | 0.17 | 0.46 | +170.6% | 15.56 | +0.6% | -1.7% | +2.0% | +3.8% | -0.5% | -1.7% | — |
| Feb 29, 2024 | AMC | 0.23 | 0.76 | +230.4% | 15.28 | +9.0% | -0.3% | +0.1% | -2.5% | +2.0% | -0.7% | — |
| Nov 1, 2023 | AMC | 0.27 | 0.98 | +263.0% | 12.42 | +6.6% | +6.9% | +2.6% | +0.1% | +0.3% | +0.5% | — |
| Aug 2, 2023 | AMC | 0.26 | 0.08 | -69.2% | 13.18 | -0.6% | +0.0% | +3.0% | -0.2% | +0.9% | +0.0% | — |
| May 9, 2023 | AMC | 0.23 | 0.42 | +82.6% | 11.56 | +1.7% | +5.5% | +1.9% | +1.9% | +1.9% | +2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $24.24 | $25.00 | +3.1% | -2.9% | -2.5% | -0.6% | -2.3% | +1.9% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.14 | $20.71 | +2.8% | -1.1% | +0.7% | +0.1% | -0.4% | +0.0% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $18.23 | $19.85 | +8.9% | +12.9% | +1.4% | +0.0% | +4.9% | +1.7% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.34 | $18.96 | +3.4% | +7.1% | +2.2% | +2.6% | +1.3% | +0.2% |
| May 10 | EF Hutton | Maintains | Buy → Buy | — | $11.56 | $11.76 | +1.7% | +5.5% | +1.9% | +1.9% | +1.9% | +2.6% |
| Apr 20 | EF Hutton | Maintains | Buy → Buy | — | $11.85 | $11.85 | +0.0% | -0.1% | +1.2% | -1.5% | -0.6% | +1.2% |
| Mar 3 | EF Hutton | Maintains | Buy → Buy | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.3% | -1.2% | +0.6% | -2.1% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.3% | -1.2% | +0.6% | -2.1% |
| Mar 3 | Morgan Stanley | Maintains | Underweight → Underweight | — | $10.93 | $10.93 | +0.0% | +0.5% | +0.3% | -1.2% | +0.6% | -2.1% |
| Jan 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $12.94 | $12.73 | -1.6% | -3.9% | -0.1% | +2.1% | +0.1% | -1.7% |
| Oct 13 | Morgan Stanley | Maintains | Underweight → Underweight | — | $12.95 | $12.91 | -0.3% | +3.2% | -1.0% | +2.2% | +1.1% | -1.8% |
| Aug 8 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.44 | $14.46 | +0.1% | +2.4% | -2.8% | +0.9% | -0.2% | +1.9% |
| Jul 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.72 | $14.57 | -1.0% | -2.1% | +2.9% | -1.8% | +0.0% | -0.5% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.58 | $14.61 | +0.2% | -1.2% | +0.8% | +1.4% | -2.1% | +2.9% |
| Apr 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $19.15 | $19.27 | +0.6% | +1.5% | -0.7% | -1.4% | -2.6% | -2.5% |
| Feb 23 | Morgan Stanley | Maintains | Underweight → Underweight | — | $19.19 | $19.76 | +3.0% | -0.1% | +0.5% | +0.6% | -0.9% | -2.8% |
| Feb 11 | EF Hutton | Maintains | Buy → Buy | — | $18.00 | $17.81 | -1.1% | +6.9% | +2.4% | -0.1% | +2.8% | -1.5% |
| Nov 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $10.65 | $10.82 | +1.6% | +1.7% | -0.7% | +2.6% | -1.5% | +1.5% |
| Apr 27 | Stifel | Maintains | Hold → Hold | — | $14.46 | $14.31 | -1.0% | -1.6% | +1.9% | +0.7% | -1.0% | -0.5% |
| Nov 20 | Deutsche Bank | Maintains | Hold → Hold | — | $13.06 | $13.04 | -0.2% | +0.8% | +1.8% | +0.1% | -1.2% | -1.1% |
| Oct 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.75 | $14.75 | +0.0% | -2.9% | -1.1% | -1.6% | -0.8% | +0.5% |
| Oct 31 | TD Cowen | Upgrade | Market Perform → Outperform | — | $9.60 | $9.90 | +3.1% | +7.3% | -1.3% | -2.8% | -5.3% | +2.9% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 11,555,209 | $262M | New | Jun 2026 |
| 2 | Vanguard Portfolio Management Llc | 4,220,273 | $96M | — | Jun 2026 |
| 3 | Renaissance Technologies Llc | 4,036,532 | $92M | — | Jun 2026 |
| 4 | Vanguard Capital Management Llc | 3,158,053 | $72M | Added | Jun 2026 |
| 5 | Millennium Management Llc | 2,541,109 | $58M | Added | Jun 2026 |
| 6 | Morgan Stanley | 2,837,478 | $57M | — | Dec 2025 |
| 7 | Systematic Financial Management Lp | 2,024,082 | $47M | Reduced | Mar 2026 |
| 8 | Arrowstreet Capital, Limited Partnership | 1,887,570 | $44M | Reduced | Mar 2026 |
| 9 | Boston Partners | 1,927,959 | $44M | Added | Jun 2026 |
| 10 | Bank Of America Corp /de/ | 1,619,994 | $38M | Added | Mar 2026 |
| 11 | Marshall Wace, Llp | 1,504,411 | $35M | Added | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 1,032,807 | $23M | Reduced | Jun 2026 |
| 13 | Invesco Ltd. | 904,282 | $21M | Added | Mar 2026 |
| 14 | Qube Research & Technologies Ltd | 786,107 | $18M | Reduced | Mar 2026 |
| 15 | Northern Trust Corp | 774,303 | $18M | Added | Mar 2026 |
| 16 | Man Group Plc | 744,791 | $17M | Reduced | Mar 2026 |
| 17 | Nuveen, Llc | 667,466 | $15M | Added | Jun 2026 |
| 18 | William Blair Investment Management, Llc | 642,176 | $15M | Added | Jun 2026 |
| 19 | Aqr Capital Management Llc | 549,553 | $12M | Added | Jun 2026 |
| 20 | Victory Capital Management Inc | 523,415 | $12M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.56B
Enterprise Value
$1.50B
P/E (TTM)
5.16x
Forward P/E
11.04x
PEG Ratio
0.01x
P/B
1.21x
P/S
4.04x
P/FCF
9.15x
EV/EBITDA
1.82x
Shares Out
84.8M
Financials (TTM)
Revenue
$443.4M
Net Income
$357.2M
EBITDA
$823.3M
Free Cash Flow
$195.8M
Op Cash Flow
$196.9M
EPS Basic
$4.02
EPS Diluted
$4.10
EPS Forward
$1.91
Gross Margin
73.1%
Op Margin
36.7%
Net Margin
80.6%
Balance Sheet
Total Assets
$1.64B
Total Liab.
$462.3M
Total Equity
$1.17B
Cash
$550.9M
LT Debt
$257.7M
Book Value/Sh
$17.40
Debt/Equity
0.23x
Current Ratio
14.64
Quick Ratio
13.85
Returns & Growth
ROE
23.1%
ROA
16.6%
ROIC
8.6%
Rev Growth YoY
+18.5%
EPS Growth YoY
+986.5%
Price Returns
2W
-1.0%
1M
-1.6%
3M
-6.7%
6M
-4.3%
12M
+10.2%
Technicals
52W High
$25.15
52W Low
$16.52
50d MA
$21.19
200d MA
$21.76
RSI (14)
53.40
ATR (14)
$0.42
Beta
0.40
Avg Volume
730K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Sep 8, 2015
Analyst Price Targets
Consensus
$37.67
High
$46.00
Low
$32.00
Median
$35.00
Data updated apr 25, 2026 3:54pm
· Source: financialmodelingprep.com